Regenxbio shares surged 23.4% in mid-day trading to $8.55, following a regulatory development that altered investor perceptions of the gene therapy approval landscape. The move came after a peer company received a clear signal from the U.S. Food and Drug Administration regarding the acceptability of three-year Phase I/II data as the primary basis for a Biologics License Application under the accelerated approval pathway.
uniQure disclosed today that, after a Type B meeting with the FDA, the agency confirmed that three-year Phase I/II data for its Huntington’s disease candidate AMT-130 would be acceptable as the main foundation for a BLA under accelerated approval. That confirmation functioned as a sector-wide regulatory green light and directly improved the market’s view of companies seeking accelerated approval based on multi-year early-stage data.
The uniQure announcement resonated strongly at Regenxbio because the company has been contending with regulatory uncertainty for RGX-202, its gene therapy candidate for Duchenne muscular dystrophy, for which Regenxbio is targeting a BLA submission under the accelerated approval route. Investor concerns about the regulatory setup for RGX-202 had pressured the stock, even after positive clinical results.
Goldman Sachs had previously lowered its price target on Regenxbio to $10 from $12 while keeping a Neutral rating, citing the regulatory questions that followed topline data for RGX-202. The FDA clarification for uniQure effectively signaled a more constructive agency posture toward gene therapy accelerated approvals, easing one of the principal overhangs that had pushed Regenxbio shares toward a 52-week low of $5.46.
The rally also built on Regenxbio’s own clinical progress. The company reported positive topline results from the pivotal Phase III AFFINITY DUCHENNE study of RGX-202 on May 14, 2026, with the primary endpoint achieved at high statistical significance. Despite that outcome, the share price had remained under pressure amid lingering questions about the regulatory path.
Market internals showed the move was not driven by broad market strength. The S&P 500 and the Nasdaq were trading essentially flat, which highlights that the rebound in Regenxbio shares was driven by sector-specific regulatory sentiment rather than a general market upturn.
A confluence of factors helped propel the stock higher: Regenxbio’s strong Phase III topline data, the reduction of regulatory uncertainty after the FDA-uniQure interaction, and the stock’s deeply depressed valuation near multi-year lows. Those elements created conditions conducive to sharp short-covering and momentum trading, lifting shares from an open of $7.18 to an intraday high of $8.62 before settling near $8.55 at mid-day.
Investors will likely continue to monitor how the FDA’s stance expressed in the uniQure meeting affects review expectations for other gene therapies pursuing accelerated approval, as well as any further guidance that could clarify acceptable evidentiary standards for BLAs in the sector.
Key points
- Regenxbio shares rose 23.4% to $8.55 in mid-day trading after a positive regulatory signal in the gene therapy sector.
- The FDA confirmed that three-year Phase I/II data for uniQure’s AMT-130 would be acceptable as the primary basis for a BLA under accelerated approval.
- Regenxbio reported positive topline results from the Phase III AFFINITY DUCHENNE study of RGX-202 on May 14, 2026, with the primary endpoint met at high statistical significance.
Risks and uncertainties
- Regulatory uncertainty remains a material factor for gene therapy developers and can significantly affect equity valuations in the biotech sector.
- Despite strong clinical data, investor sentiment can be volatile and driven by evolving regulatory guidance specific to accelerated approval pathways.